BNN.DE
BRAIN Biotechnology Research and Information Network AG
Price:  
1.95 
EUR
Volume:  
4,325
Germany | Chemicals

BNN.DE WACC - Weighted Average Cost of Capital

The WACC of BRAIN Biotechnology Research and Information Network AG (BNN.DE) is 6.0%.

The Cost of Equity of BRAIN Biotechnology Research and Information Network AG (BNN.DE) is 6.05%.
The Cost of Debt of BRAIN Biotechnology Research and Information Network AG (BNN.DE) is 6.35%.

RangeSelected
Cost of equity5.2% - 6.9%6.05%
Tax rate6.1% - 8.7%7.4%
Cost of debt5.7% - 7.0%6.35%
WACC5.3% - 6.7%6.0%
WACC

BNN.DE WACC calculation

CategoryLowHigh
Long-term bond rate2.8%3.3%
Equity market risk premium5.1%6.1%
Adjusted beta0.380.43
Additional risk adjustments0.5%1.0%
Cost of equity5.2%6.9%
Tax rate6.1%8.7%
Debt/Equity ratio
0.620.62
Cost of debt5.7%7.0%
After-tax WACC5.3%6.7%
Selected WACC6.0%

BNN.DE's CAPM model and how its cost of Equity is calculated

The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.

This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.

Here’s how we figure out the cost of equity for BNN.DE:

cost_of_equity (6.05%) = risk_free_rate (3.05%) + equity_risk_premium (5.60%) * adjusted_beta (0.38) + risk_adjustments (0.75%)

We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.